Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
3
×
boston top stories
life sciences
national blog main
3
×
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
national
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
advaxis
age related macular degeneration
agios pharmaceuticals
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
american society of hematology
amgen
andrew oxtoby
babies
beta-thalassemia
biotech
blood diseases
What
big
3
×
week
3
×
ceo
medicine
aces
american
announced
ash
bio
blood
bosley's
bosley’s
bridge
bucks
cas
cholesterol
country
crime
crispr
departure
diego
disease
drug
editas
exit
flexible
gathering
guiding
hematology’s
inclisiran
katrine
key
largest
lowering
meant
medco
medical
medicines
meeting
moves
Language
unset
Current search:
week
×
" boston blog main "
×
" national blog main "
×
big
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On